A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1451-1467

  Montanya, Eduard ^a,b,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Exenatide; GLP 1 receptor agonists; Liraglutide; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; CALCITONIN; EXENATIDE EXTENDED RELEASE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84863106349     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.692777     Document Type: Review

References (111)

1. Stratton I, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
2. Hoerger TJ, Segel JE, Gregg EW, Saadine JB. US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes. Diabetes Care 2008;31:81-6
3. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
4. Nicolucci A, Rossi MC. Incretin-based therapies: A new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008;79:184-91
5. Frier BM How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:8-92
6. Handelsman Y, Blonde L, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl 2):S1-53
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centred approach. Diabetes Care 2012;35:1364-79
8. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
9. Drucker DJ, Nauck MA. the incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
11. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-13
12. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23
13. Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:737-45
14. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia 2011;54:10-18
15. Kjems LL, Holst JJ, Volund A, Madsbad S. the influence of GLP-1 on glucose stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and non-diabetic subjects. Diabetes 2003;52:380-6
16. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36:741-4
17. Meier JJ, Gallwitz B, Salmen S, et al. Normalisation of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25
18. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002;359:824-30
19. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hyrolyses gastric inhibitory polypeptide, glucagon-like peptide 1 (7-39)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
20. Novo Nordisk Ltd. Victoza (liraglutide) summary of product characteristics. 2012.Available from: http://emc. medicines.org.uk/medicine/ 21986/SPC/Victoza+6+mg%2Fml+solution+for +injection+in+pre-filled+pen/ [Last accessed 14 March 2012]
21. Amylin Pharmaceuticals/Eli Lilly. Byetta (exenatide) summary of product characteristics. 2009.Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000698/WC500051845.pdf [Last accessed 14 March 2012]
22. Eli Lilly and Co. Ltd. Bydureon summary of product characteristics. 2011.Available from: http://www. medicines.org.uk/EMC/medicine/24665/SPC/ BYDUREON+2+mg+powder+and +solvent+for+prolonged-release +suspension+for+injection/ [Last accessed 14 March 2012]
23. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. on behalf of the EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-31
24. Rosenstock J, Reusch J, Bush M, et al. Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
25. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomized, parallel-group, open label trial. Lancet 2010;375:1447-56
26. Bergenstal RM, Wysham C, MacConell L, et al. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-9
27. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care 2012;35:252-8
28. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5
29. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once-weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
30. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74
31. DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54
32. Garber A, Henry R, Ratner R, et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): Randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
33. Nauck MA, Frid A, Hermansen K, et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009;32:84-90
34. Marre M, Shaw J, Brandle M, et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1). Diabet Med 2009;26:268-78
35. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
36. Zinman B, Gerich J, Buse JB, et al. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4). Diabetes Care 2009;32:1224-30
37. Russell-Jones D, Vaag A, Schmitz O, et al. on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: A randomised controlled trial (LEAD-5). Diabetologia 2009;52:2046-55
38. DeVries JH, Bain SC, Rodbard HW, et al. on behalf of the Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;doi:10.2337/DC11- 1928.
39. Buse JB, Henry RR, Han J, et al. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
40. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
41. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
42. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60.Erratum: 2008;30:1937
43. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. the effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2007;146:477-85
44. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103-12
45. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 2010;375:2234-43
46. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10
47. Buse JB, Nauck MA, First T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): A randomised, open-label study [abstract 75]. Diabetologia 2011;54(Suppl 1):S38
48. Garber A, Henry RR, Ratner R, et al. LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-56
49. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28
50. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
51. Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9
52. Buse JB, Sesti G, Schmidt WE, et al. Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3
53. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycaemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
54. Ryder REJ, Thong KY, Cull ML, et al. the association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits [abstract 804]. Diabetologia 2011;54(Suppl 1):S326
55. Agersø H, Jensen LB, Elbrønd B, et al. the pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLPE 1 derivative, in healthy men. Diabetologia 2002;45:195-202
56. Kolterman OG, Kimm DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
57. Sturis J, Gotfredsen CF, Rømer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32
58. Rolin B, Larsen MO, Gotfredsen CF, et al. the long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52
59. Best JH, Pelletier EM, Herman WH, et al. Risk of cardiovascular events in patients with diabetes treated with exenatide or other glucose-lowering therapies; a retrospective analysis of the LifeLink- Database [abstract 712-P]. Diabetes 2010;59(Suppl 1):A194
60. Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
61. Fonseca V, Falahati A, Zychma M, et al. Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes [poster D-0908]. IDF 2009 20th World Congress Abstract Book, IDF; Montreal, Canada, 2009. p. 310
62. Plutzky J, Garber A, Toft AD, Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes [abstract 762]. Diabetologia 2009;52(Suppl 1):S299
63. Russell-Jones D, Sesti G, Garber A, et al. Liraglutide causes reductions in body weight both in patients with and without gastrointestinal side effects [abstract 1886-P]. Diabetes 2010;59(Suppl 1):A493
64. Eli Lilly. DURATION-6 Top-Line Study Results Announced. 2011.Available from: https://investor.lilly. com/releasedetail2.cfm? ReleaseID=554248 [Last accessed 16 February 2012]
65. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96:1695-702
66. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: Safety, efficacy and cross-reactivity with long-term treatment Diabetes Obes Metab. 2012;14:546-54
67. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetized pigs. Diabetologia 2006;49:706-12
68. Malm-Erjefalt M, Bjørnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38:1944-53
69. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-55
70. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010; 70:807-14
71. US Food and Drug Administration. Information for Healthcare Professionals: Exenatide (marketed as Byetta) - 8/2008 Update. 2008.Available from: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationfor PatientsandProviders/ucm124713.htm [Last accessed 14 March 2012]
72. US Food and Drug Administration. Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). 2009.Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm183764.htm [Last accessed 14 March 2012]
73. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
74. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
75. Pendergrass M, Chen W. Association between diabetes, exenatide, sitagliptin and acute pancreatitis. Diabetes 2010;59(Suppl 1):A160; 587-P
76. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
77. Wenten M, Gaebler J, Hussein M, et al. A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other antidiabetic medication: A follow-up study. Diabetes 2010;59(Suppl 1): A163; 596-P
78. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-66
79. US Food and Drug Administration. Victoza highlights of prescribing information. 2011.Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/022341s004lbl.pdf [Last accessed 14 March 2012]
80. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22
81. Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 2012;69:386-9
82. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
83. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
84. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96:853-60
85. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012;153:1538-47
86. US Food and Drug Administration. Bydureon highlights of prescribing information. 2012.Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/022200s000lbl.pdf [Last accessed 27 March 2012]
87. American Association of Clinical Endocrinologists. AACE Statement on liraglutide. 2010.Available from: https://www.aace.com/publications/online-news/ March-16-2010 [Last accessed 27 February 2012]
88. US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat type 2 Diabetes. 2008.Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm071627.pdf [Last accessed 27 February 2012]
89. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase II: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8:237-40
90. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22
91. Linnebjerg H, Seger M, Kothare P, et al. the effect of exenatide on QTc interval in healthy subjects [abstract 597-P]. Diabetes 2009;58(Suppl 1):A161
92. Sager P, Darpo B, Han J, et al. Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes [abstract 1070-P]. Diabetes 2011;60(Suppl 1):A294
93. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;11:1353-62
94. Bergenstal R, Daniels G, Mann J, et al. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER-) trial: Rationale and study design [abstract 2303-PO]. Diabetes 2011;59(Suppl 1):A612-13
95. Bradley C. the diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C, editor. Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice. Harwood Academic Publishers; Chur, Switzerland: 1994
96. Schmidt WE, Christiansen JS, Hammer M, et al. Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: Results from a randomized, open-label study. Diabet Med 2011;28:715-23
97. Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009;26:722-8
98. Smith IC, Chubb B, Valentine W. Cost-effectiveness of liraglutide compared to exenatide in combination with metformin and/or sulphonylurea [poster 406]. Diabet Med 2010;27(Suppl 1):37-188
99. Schlander M, Mentrup S, Lund N. Addition of incretin-therapy to metformin in type-2-diabetes mellitus (T2DM): Cost-effectiveness of liraglutide versus sitagliptin from the perspective of the German Statutory Health Insurance (SHI). Value Health 2010;13:A291
100. Macconell L, Malloy J, Huang W, et al. Safety and efficacy of once-monthly exenatide over 20 weeks in patients with type 2 diabetes [abstract 46-LB]. Presented at the American Diabetes Association 71st Scientific Sessions; 2011
101. Luskey K, Rosenstock J, Alessi T, Henry RR. Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS- device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes [abstract 77]. Diabetologia 2011;54(Suppl 1):S39
102. Astrup A, Rossner S, Van Gaal L, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
103. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011;doi:10.1038/ijo.2011.158
104. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:2670-8
105. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-5
106. Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study. Obesity (Silver Spring) 2012;20:364-70
107. Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011;96:E1314-19
108. Raman VS, Mason KJ, Rodriguez LM, et al. the role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294-6
109. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84
110. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463-8
111. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007;83:24-8